ARTICLE | Translation in Brief
Neo opportunities in glioblastoma
BioNTech, Immatics lay groundwork for personalized glioblastoma immunotherapy
January 3, 2019 2:01 PM UTC
Phase I results from a consortium led by BioNTech AG and Immatics Biotechnologies GmbH convinced both companies that personalized immunotherapies can turn on T cell activity in glioblastoma, an immunologically "cold" cancer.
The study is one of the first two reports of neoantigen vaccines in glioblastoma in the clinic. In the same issue of Nature, a Dana-Farber Cancer Institute group showed similar results with a different vaccination strategy...